We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01047189
First Posted: January 12, 2010
Last Update Posted: November 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Medicis Pharmaceutical Corporation
Information provided by (Responsible Party):
Wake Forest University Health Sciences ( Wake Forest University )
Results First Submitted: July 1, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Single (Investigator);   Primary Purpose: Treatment
Condition: Acne Vulgaris
Interventions: Drug: clindamycin phosphate 1.2% and tretinoin 0.025%
Drug: clindamycin 1% gel
Drug: tretinoin 0.025% cream

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were recruited from IRB approved advertising and the Wake Forest University Health Sciences Dermatology Clinic

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Ziana Gel Ziana gel (clindamycin phosphate 1.2% and tretinoin 0.025%) applied once daily for 12 weeks
Clindamycin Plus Tretinoin Applied Separately Generic clindamycin 1% gel plus tretinoin 0.025% cream

Participant Flow:   Overall Study
    Ziana Gel   Clindamycin Plus Tretinoin Applied Separately
STARTED   13   13 
COMPLETED   9   13 
NOT COMPLETED   4   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Ziana Gel Ziana gel (clindamycin phosphate 1.2% and tretinoin 0.025%) applied once daily for 12 weeks
Clindamycin Plus Tretinoin Applied Separately Generic clindamycin 1% gel plus tretinoin 0.025% cream
Total Total of all reporting groups

Baseline Measures
   Ziana Gel   Clindamycin Plus Tretinoin Applied Separately   Total 
Overall Participants Analyzed 
[Units: Participants]
 13   13   26 
Age 
[Units: Participants]
Count of Participants
     
<=18 years      7  53.8%      2  15.4%      9  34.6% 
Between 18 and 65 years      6  46.2%      11  84.6%      17  65.4% 
>=65 years      0   0.0%      0   0.0%      0   0.0% 
Age 
[Units: Years]
Mean (Full Range)
 20.1 
 (13 to 35) 
 26.2 
 (15 to 40) 
 23.1 
 (13 to 40) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
     
Female      9  69.2%      6  46.2%      15  57.7% 
Male      4  30.8%      7  53.8%      11  42.3% 
Region of Enrollment 
[Units: Participants]
     
United States   13   13   26 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Measured Adherence to ZIANA Gel or Generic Topical Clindamycin 1% Gel Each Morning Plus Generic Topical Tretinoin 0.025% Cream Each Evening in Subjects With Mild to Moderate Acne   [ Time Frame: 12 weeks ]

2.  Secondary:   The Change (Dynamic Assessment) From Baseline to Week 12 (or End of Treatment) in Total Acne Lesion Count   [ Time Frame: Baseline to 12 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Steven Feldman, MD, PhD
Organization: Wake Forest University Health Sciences
phone: 336-716-3775
e-mail: sfeldman@wfubmc.edu



Responsible Party: Wake Forest University Health Sciences ( Wake Forest University )
ClinicalTrials.gov Identifier: NCT01047189     History of Changes
Other Study ID Numbers: 00007137
First Submitted: January 11, 2010
First Posted: January 12, 2010
Results First Submitted: July 1, 2011
Results First Posted: October 17, 2011
Last Update Posted: November 6, 2017